Emmanouil V. Dermitzakis - Search Results

Year	Number of Results
2009	2
2010	2
2016	2
2017	1
2018	1
2019	1
2020	2
2021	1
2022	8
2023	7
2024	3

1

OnabotulinumtoxinA Add-On to Monoclonal Anti-CGRP Antibodies in Treatment-Refractory Chronic Migraine.

Argyriou AA, Dermitzakis EV, Xiromerisiou G, Vikelis M. Argyriou AA, et al. Among authors: dermitzakis ev. Toxins (Basel). 2022 Dec 2;14(12):847. doi: 10.3390/toxins14120847. Toxins (Basel). 2022. PMID: 36548744 Free PMC article.

2

Single OnabotulinumtoxinA Session Add-On to Carbamazepine or Oxcarbazepine in Treatment-Refractory Trigeminal Neuralgia: A Case Series with 24-Week Follow Up.

Xiromerisiou G, Lampropoulos IC, Dermitzakis EV, Vikelis M, Marogianni C, Mysiris D, Argyriou AA. Xiromerisiou G, et al. Among authors: dermitzakis ev. Toxins (Basel). 2023 Aug 31;15(9):539. doi: 10.3390/toxins15090539. Toxins (Basel). 2023. PMID: 37755965 Free PMC article.

3

Predictors of Response to Fremanezumab in Migraine Patients with at Least Three Previous Preventive Failures: Post Hoc Analysis of a Prospective, Multicenter, Real-World Greek Registry.

Argyriou AA, Dermitzakis EV, Xiromerisiou G, Rallis D, Soldatos P, Litsardopoulos P, Vikelis M. Argyriou AA, et al. Among authors: dermitzakis ev. J Clin Med. 2023 Apr 29;12(9):3218. doi: 10.3390/jcm12093218. J Clin Med. 2023. PMID: 37176658 Free PMC article.

4

Effects of Fremanezumab on Psychiatric Comorbidities in Difficult-to-Treat Patients with Chronic Migraine: Post Hoc Analysis of a Prospective, Multicenter, Real-World Greek Registry.

Vikelis M, Dermitzakis EV, Xiromerisiou G, Rallis D, Soldatos P, Litsardopoulos P, Rikos D, Argyriou AA. Vikelis M, et al. Among authors: dermitzakis ev. J Clin Med. 2023 Jul 6;12(13):4526. doi: 10.3390/jcm12134526. J Clin Med. 2023. PMID: 37445560 Free PMC article.

5

Therapeutic Benefits of Short-Arm Human Centrifugation in Multiple Sclerosis-A New Approach.

Kourtidou-Papadeli C, Frantzidis CA, Bakirtzis C, Petridou A, Gilou S, Karkala A, Machairas I, Kantouris N, Nday CM, Dermitzakis EV, Bakas E, Mougios V, Bamidis PD, Vernikos J. Kourtidou-Papadeli C, et al. Among authors: dermitzakis ev. Front Neurol. 2022 Jan 4;12:746832. doi: 10.3389/fneur.2021.746832. eCollection 2021. Front Neurol. 2022. PMID: 35058870 Free PMC article.

6

Reporting Quality and Risk of Bias Analysis of Published RCTs Assessing Anti-CGRP Monoclonal Antibodies in Migraine Prophylaxis: A Systematic Review.

Rikos D, Vikelis M, Dermitzakis EV, Soldatos P, Rallis D, Rudolf J, Andreou AP, Argyriou AA. Rikos D, et al. Among authors: dermitzakis ev. J Clin Med. 2024 Mar 28;13(7):1964. doi: 10.3390/jcm13071964. J Clin Med. 2024. PMID: 38610729 Free PMC article. Review.

7

Long-term adherence, safety, and efficacy of repeated onabotulinumtoxinA over five years in chronic migraine prophylaxis.

Argyriou AA, Dermitzakis EV, Vlachos GS, Vikelis M. Argyriou AA, et al. Among authors: dermitzakis ev. Acta Neurol Scand. 2022 Jun;145(6):676-683. doi: 10.1111/ane.13600. Epub 2022 Feb 15. Acta Neurol Scand. 2022. PMID: 35170031

8

Results of a Web-based survey of 2105 Greek migraine patients in 2020: demographics, clinical characteristics, burden and the effects of the COVID-19 pandemic on the course of migraine.

Dermitzakis EV, Kouroudi A, Argyriou AA, Spingos KC, Bilias K, Vikelis M. Dermitzakis EV, et al. BMC Neurol. 2022 Nov 21;22(1):440. doi: 10.1186/s12883-022-02968-9. BMC Neurol. 2022. PMID: 36411425 Free PMC article.

9

Onabotulinumtoxin-A treatment in Greek patients with chronic migraine.

Vikelis M, Argyriou AA, Dermitzakis EV, Spingos KC, Mitsikostas DD. Vikelis M, et al. Among authors: dermitzakis ev. J Headache Pain. 2016 Dec;17(1):84. doi: 10.1186/s10194-016-0676-z. Epub 2016 Sep 17. J Headache Pain. 2016. PMID: 27640152 Free PMC article. Clinical Trial.

10

Genetic Variability in Vitamin D Receptor and Migraine Susceptibility: A Southeastern European Case-Control Study.

Papasavva M, Vikelis M, Siokas V, Katsarou MS, Dermitzakis EV, Raptis A, Dardiotis E, Drakoulis N. Papasavva M, et al. Among authors: dermitzakis ev. Neurol Int. 2023 Sep 5;15(3):1117-1128. doi: 10.3390/neurolint15030069. Neurol Int. 2023. PMID: 37755360 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

25 results

Results by year

Search Page

Filters

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

Search Results

25 results

Results by year